Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/14/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Gilad Rosenberg MD

Wrong Dr. Gilad Rosenberg MD?

Vice President, Clinical Developm...

Phone: (609) ***-****  HQ Phone
Email: a***@***.com
D-Pharm Ltd
47 Hulfish Street Suite 310
Princeton , New Jersey 08642
United States

Company Description: D-Pharm utilizes its proprietary platform technology for the design of novel drugs, mainly for treatment of major CNS disorders. In addition, the company intends to...   more

Employment History

  • Vice President for Clinical Development
21 Total References
Web References
Dr. Gilad Rosenberg, ..., 14 Jan 2014 [cached]
Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development, commented: "There is currently no effective specific treatment for acute pancreatitis, and patients only receive symptomatic therapy.
D-Pharm’s VP for Clinical Development, ..., 2 Jan 2014 [cached]
D-Pharm’s VP for Clinical Development, Dr. Gilad Rosenberg added; “I’m happy to be involved in this clinical trial that may ultimately benefit stroke patients and I’m looking forward to swift patient enrolment.
Similarly, THR-18 reduced by more than ... [cached]
Similarly, THR-18 reduced by more than twice the occurrence of brain edema (p Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development commented, "It is certainly encouraging to see the reduced rates of brain swelling and intracranial bleeding in the tPA-treated stroke patients given THR-18, and I look forward to see whether these findings translate into less disability and better neurological recovery once the clinical endpoint data become available for the full data set."
D-Pharm's VP for Clinical Development, ..., 16 Oct 2013 [cached]
D-Pharm's VP for Clinical Development, Dr. Gilad Rosenberg, commented: "We are excited to continue the clinical testing of THR-18.
NeuroNE - 26th July 2005 PR, 26 July 2005 [cached]
Dr Gilad Rosenberg, VP Clinical Development at D-Pharm added: "We are very encouraged by the fact that this is the second Phase II clinical study in which we observe beneficial effects of DP-b99 on ischemic stroke outcomes.
Other People with the name "Rosenberg":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.